Journal: Journal of Pharmaceutical Analysis

Article Title: Targeting SH3GL1 for prognosis and immune response in breast cancer

doi: 10.1016/j.jpha.2025.101377

Figure Lengend Snippet: SH3-domain containing GRB2-like 1 ( SH3GL1 ) is generally highly expressed in breast cancer (BRCA) and is closely related to a variety of immune cells. (A) Hematoxylin and eosin (H&E) staining diagram of BRCA and immunohistochemistry (IHC) staining diagram of breast markers, including pan-cytokeratin, estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2). (B) Western blot analysis of the protein expression levels of SH3GL1 in tissues of BRCA and adjacent normal tissue (Adj). ∗∗∗ P < 0.001, in comparison with Adj. (C) Reverse transcription quantitative polymerase chain reaction (RT-qPCR) to detect the mRNA expression level of SH3GL1 in BRCA and Adj in clinical samples, ∗∗∗ P < 0.001, in comparison with Adj. (D) Flow cytometry for the proportion of natural killer (NK) cells, T cells, B cells, regulatory T cells (Treg), M0, M1, dendritic cell (DC) and mast cell in the tissues of BRCA and Adj, ∗∗∗ P < 0.001, in comparison with Adj. (E) RT-qPCR to detect the expression level of SH3GL1 in commonly used BRCA cell lines. Among them, MCF-10A was normal breast epithelial cell, BT474: three Yang; SKBR3: HER2 high expression; MCF-7: ER + ; MDA-MB-453: ER-HER2 + ; MDA-MB-231: Three Yin. ∗ indicates comparison with MCF-10A. ∗∗ P < 0.01, ∗∗∗ P < 0.001. (F, G) Western blot analysis of the protein expression level of SH3GL1 in commonly used BRCA cell lines. In comparison with MCF-10A, ∗ P < 0.01, ∗∗ P < 0.01, ∗∗∗ P < 0.001. The expression values for different cell types were not ordered according to any specific rank. M0/M1: macrophage subtypes. TNBC: triple-negative breast cancer; GAPDH: glyceraldehyde-3-phosphate dehydrogenase. BCRA-1 and BCRA-2 represent breast cancer samples obtained from two independent patients.

Article Snippet: In this study, the BRCA cell lines BT474 (human breast ductal carcinoma cell line, BFN60700229), SKBR3 (human BRCA cell line, BFN60700185), MCF-7 (human BRCA cell line, BFN607200603), MDA-MB-231 (human BRCA cell line, BFN608008564), and MDA-MB-453 (human BRCA cell line, BFN60700116), as well as the normal breast cell line MCF-10A (human breast epithelial cells, BFN60805246) were all purchased from BLUEFBIO (Shenzhen, Guangdong, China) and authenticated by the German DSMZ Leibniz Research Institute in November 2017 and June 2018 using a nano-composite PCR-based (short tandem repeat) STR profile.

Techniques: Staining, Immunohistochemistry, Western Blot, Expressing, Comparison, Reverse Transcription, Real-time Polymerase Chain Reaction, Quantitative RT-PCR, Flow Cytometry

Journal: Journal of Pharmaceutical Analysis

Article Title: Targeting SH3GL1 for prognosis and immune response in breast cancer

doi: 10.1016/j.jpha.2025.101377

Figure Lengend Snippet: SH3-domain containing GRB2-like 1 ( SH3GL1 ) in breast cancer (BRCA) epithelial cells promotes their interaction with immune cells. (A) The mRNA expression level of SH3GL1 in normal organoids (Normal-Orgs) and BRCA organoids (BRCA-Orgs) was detected by reverse transcription quantitative polymerase chain reaction (RT-qPCR). ∗∗ P < 0.01, in comparison with Normal-Orgs. (B) Western blot analysis of SH3GL1 protein expression in Normal-Orgs and BRCA-Orgs. ∗∗ P < 0.01, in comparison with Normal-Orgs. (C) RT-qPCR to detect the mRNA expression level of SH3GL1 in BRCA-Orgs and BT474 before and after co-culture. (D) Western blot analysis of SH3GL1 protein levels in BRCA-Orgs and BT474 before and after co-culture. (E) RT-qPCR to detect mRNA expression of tumor susceptibility marker CD44 in BRCA-Orgs and BT474 before and after co-culture. (F) Representative pictures of proliferating marker Ki67 in BRCA-Orgs before and after co-culture detected by IHC. (G) Statistics of the maximum passage times of BRCA-Orgs before and after co-culture. (H) Statistics on the number of BRCA-Orgs formed from single cells to organoids before and after co-culture. (I) Representative pictures of 5-ethynyl-2′-deoxyuridine (EdU) staining of BT474 cells before and after co-culture. The right side is the relative statistical map of EdU positive cells. (J) Representative images of scratch migration experiment of BT474 cells before and after co-culture. Statistical map of relative scratch closure area on the right. (K) RT-qPCR to detect the mRNA expression of SH3GL1 before and after co-culture of BRCA-Orgs and MDA-MB-231 after knockdown of SH3GL1 . (L,M) Western blot analysis of SH3GL1 protein expression in BRCA-Orgs and MDA-MB-231 cells before and after co-culture after SH3GL1 knockdown (L), and the statistical chart (M). (N) Representative pictures of proliferation marker Ki67 before and after co-culture detected by IHC after BCRA-Orgs SH3GL1 knockdown, and statistical graph. (O) Representative pictures of EdU staining of MDA-MB-231 cells before and after co-culture after SH3GL1 knockdown (red is EdU positive cells), and the relative statistical map of EdU positive cells. (P) Representative images of scratch migration experiment of MDA-MB-231 cells before and after co-culture after SH3GL1 knockdown, and statistical map of relative scratch closure area. In the D–P plots, ∗∗ P < 0.01, ∗∗∗ P < 0.001. (Q) Representative picture of transwell migration induced PBMC (T cells) to BRCA-Orgs, Where fluorescence represents T cells, and statistical graph on the right. In the Q plot, ∗∗∗ P < 0.001, in comparison with Normal-Orgs or shNC. IHC: immunohistochemistry; CD44: tumor susceptibility marker; transwell: migration assay system; PBMC: peripheral blood mononuclear cells.

Article Snippet: In this study, the BRCA cell lines BT474 (human breast ductal carcinoma cell line, BFN60700229), SKBR3 (human BRCA cell line, BFN60700185), MCF-7 (human BRCA cell line, BFN607200603), MDA-MB-231 (human BRCA cell line, BFN608008564), and MDA-MB-453 (human BRCA cell line, BFN60700116), as well as the normal breast cell line MCF-10A (human breast epithelial cells, BFN60805246) were all purchased from BLUEFBIO (Shenzhen, Guangdong, China) and authenticated by the German DSMZ Leibniz Research Institute in November 2017 and June 2018 using a nano-composite PCR-based (short tandem repeat) STR profile.

Techniques: Expressing, Reverse Transcription, Real-time Polymerase Chain Reaction, Quantitative RT-PCR, Comparison, Western Blot, Co-Culture Assay, Marker, Staining, Migration, Knockdown, Fluorescence, Immunohistochemistry, Transwell Migration Assay

Journal: Oncotarget

Article Title: Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells

doi: 10.18632/oncotarget.20261

Figure Lengend Snippet: ( A – D ) Carfilzomib and bortezomib induce cell death in a concentration-dependent manner. (A) and (C) Equal numbers of BT474 or MDA-MB-361 cells were seeded on 12-well culture plates and treated with the indicated carfilzomib or bortezomib concentrations. After 10 days cells were fixed and stained. (B) and (D) BT474 and MDA-MB-361 cells were cultured in the presence of the indicated carfilzomib and bortezomib concentrations for 32 hours. Western blots of protein lysates were probed with the indicated antibodies.

Article Snippet: MCF7 and T47D cells were purchased from ATCC, BT474 cells were purchased from CLS Cell Line Services GmbH (Heidelberg, Germany) and MDA-MB-361 cells were purchased from Sigma Aldrich (Taufkirchen, Germany).

Techniques: Concentration Assay, Staining, Cell Culture, Western Blot

Journal: Oncotarget

Article Title: Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells

doi: 10.18632/oncotarget.20261

Figure Lengend Snippet: ( A ) BT474 and ( B ) MDA-MB-361 cells were cultured in the presence of the indicated carfilzomib (right panels) and bortezomib (left panels) concentrations for 32 hours. Western blots of protein lysates were probed with the indicated antibodies.

Article Snippet: MCF7 and T47D cells were purchased from ATCC, BT474 cells were purchased from CLS Cell Line Services GmbH (Heidelberg, Germany) and MDA-MB-361 cells were purchased from Sigma Aldrich (Taufkirchen, Germany).

Techniques: Cell Culture, Western Blot

Journal: Oncotarget

Article Title: Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells

doi: 10.18632/oncotarget.20261

Figure Lengend Snippet: ( A ) Carfilzomib and bortezomib induce cell death in a time-dependent manner. BT474 cells were cultured in the presence or absence of the indicated carfilzomib or bortezomib concentrations. The percentage of SubG1 cells was evaluated at different time points using propidium iodide staining and flow cytometry. Mean values ± s.d. of three independent experiments are presented. ( B ) BT474 cells were cultured in the presence of 250 nM carfilzomib or 25 nM bortezomib. Cells were harvested at the indicated time points. Western blots of protein lysates were probed with the indicated antibodies. ( C ) Schematic model of a possible molecular network regulated by both proteasome inhibitors, based on the results of the Western blots and the literature. Continued activation of HER2 has a causal role in tumorigenesis and leads to tumor progression [ , ]. Activation of HER2 triggers autophosphorylation of specific tyrosine residues within its cytoplasmic domain, consequently activating different intracellular signaling pathways such as Ras-MAPK and the PI3K/Akt axis which determine cell growth, cell survival and therapy resistance to endocrine therapies. Different protein tyrosine phosphatases regulate phosphorylation of the HER2 signaling domain and are therefore important key regulators of HER2 activity [ , ]. The PEST-type protein-tyrosine phosphatase BDP1 inhibits ligand-induced activation of HER2 [ , ]. PEST sequences cause accelerated degradation by the proteasome/ubiquitin system , and PIs therefore increase the amount of BDP1 through blocking its proteasomal destruction. This in turn leads to accelarated dephosporylation and thereby inactivation of HER2 and its downstream target signaling pathways. Aberrant signaling through HER2 and other members of the HER family mediates endocrine resistance in ER+ positive breast cancer. On the other hand ERα co-expression with HER2 attenuates the efficiency of anti-HER2-targeted therapies. These findings indicate that HER2 and ERα act in concert to allow breast cancer cells to escape from both anti-ERα and anti-HER2-targeted therapies. Besides inhibiting HER2, PIs also suppress ERα protein expression.

Article Snippet: MCF7 and T47D cells were purchased from ATCC, BT474 cells were purchased from CLS Cell Line Services GmbH (Heidelberg, Germany) and MDA-MB-361 cells were purchased from Sigma Aldrich (Taufkirchen, Germany).

Techniques: Cell Culture, Staining, Flow Cytometry, Western Blot, Activation Assay, Protein-Protein interactions, Phospho-proteomics, Activity Assay, Ubiquitin Proteomics, Blocking Assay, Expressing

Journal: Oncotarget

Article Title: Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells

doi: 10.18632/oncotarget.20261

Figure Lengend Snippet: ( A ) Stable knockdown of BDP1 within BT474 cells was performed by using lentiviral transfer of non-targeted or ten different targeted shRNAs against BDP1. After transduction reduced expression of BDP1 in ten BT474 BDP1 k.o. cells was evidenced by qPCR (left panel). The two shRNAs (k.o.2 and k.o.7) with the highest potential to decrease BDP1 expression in BT474 cells at passage 2 of puromycin selection were used to quantify the degree of knockdown (right panel). ( B ) BT474 cells either transduced with non-targeted or BT474 k.o.2 and k.o.7 from passage 2 of puromycin selection were cultured in the presence or absence of carfilzomib for 28 hours. Western blots of protein lysates were probed with the indicated antibodies. ( C ) Equal numbers of BDP1 k.o.2, BDP1 k.o.7 and negative control scramble BT474 cells were seeded on 12-well culture plates and treated with the indicated carfilzomib concentrations (right panels). After 9 days cells were fixed and stained. ( D ) Macroscopic photos are shown of the fixed cell colonies for BT474 cells either untreated or treated with the indicated carfilzomib concentration. Bar 100 μm.

Article Snippet: MCF7 and T47D cells were purchased from ATCC, BT474 cells were purchased from CLS Cell Line Services GmbH (Heidelberg, Germany) and MDA-MB-361 cells were purchased from Sigma Aldrich (Taufkirchen, Germany).

Techniques: Knockdown, Transduction, Expressing, Selection, Cell Culture, Western Blot, Negative Control, Staining, Concentration Assay

Journal: Oncotarget

Article Title: Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells

doi: 10.18632/oncotarget.20261

Figure Lengend Snippet: ( A ) Equal numbers of BT474 cells were seeded on 12-well culture plates and treated with the indicated lapatinib concentrations. After 10 days cells were fixed and stained (left panel). BT474 cells were cultured in the presence of the indicated lapatinib concentrations for 32 hours. Western blots of protein lysates were probed with the indicated antibodies (right panel). ( B ) BT474 cells were cultured in the absence or in the presence of the indicated concentrations of lapatinib, bortezomib or both drugs together (left panel) or BT474 cells were cultured in the absence or presence of the indicated concentrations of lapatinib, carfilzomib or in combination (right panel). After 30 hours cells were harvested. Western blots of the protein lysates were probed with the indicated antibodies. ( C ) Equal numbers of BT474 cells were seeded on 6-well culture plates and cultured either with or without the indicated lapatinib, bortezomib or carfilzomib concentrations. After 12 days cells were fixed. Macroscopic photos are shown of the fixed cell colonies for BT474 cells treated with lapatinib, bortezomib and lapatinib plus bortezomib (upper panel) and lapatinib, carfilzomib and lapatinib plus carfilzomib (lower panel). Bar 100 μm. ( D ) To determine the induction of cell death relative to the applied lapatinib and or bortezomib/carfilzomib concentrations equal numbers of BT474 cells were seeded on 12-well culture plates and cultured in the absence or in the presence of the indicated drug concentrations for 5 days. The percentage of SubG1 cells was evaluated using propidium iodide staining and flow cytometry. Mean values ± s.d. of three independent experiments are presented.

Article Snippet: MCF7 and T47D cells were purchased from ATCC, BT474 cells were purchased from CLS Cell Line Services GmbH (Heidelberg, Germany) and MDA-MB-361 cells were purchased from Sigma Aldrich (Taufkirchen, Germany).

Techniques: Staining, Cell Culture, Western Blot, Flow Cytometry

Journal: Oncotarget

Article Title: Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells

doi: 10.18632/oncotarget.20261

Figure Lengend Snippet: ( A ) BT474 cells were cultured in the absence or presence of lapatinib concentrations > 75 nM for 9 weeks and 15 passages. Untreated parental (BT474 p.) and BT474 cells which survived and continued to grow in the presence of lapatinib (BT474 LR.) were harvested. Protein lysates were assayed by immunoblotting for the level of ERα expression. β-actin served as loading control (left upper panel). Equal amounts (5 × 10 3 ) of BT474 p. and BT474 LR. cells were seeded per well on 6-well culture plates and cultured in the presence of 100 nM lapatinib. After 12 days cells were either fixed and stained (left lower panel) or cells were harvested after 5 days to determine induction of cell death. The percentage of SubG1 cells was evaluated using propidium iodide staining and flow cytometry. Mean values ± s.d. of three independent experiments are presented (right panel). P -values < 0.05 are indicated by asterisks. ( B ) BT474 LR. cells were cultured in presence of the indicated lapatinib, bortezomib or carfilzomib concentrations. Western blots of protein lysates were probed with the indicated antibodies. ( C ) Equal amounts of BT474 p. and BT474 LR. cells were seeded on 6-well culture plates and cultured either with or without the indicated concentrations of lapatinib, bortezomib or carfilzomib, respectively. For colony forming assay the cells were fixed and stained after 12 days cells (upper panel). Macroscopic photos of the fixed cell colonies are shown in the middle panel. Bar 100 mm (middle panel). To determine the induction of cell death cells were harvested after 5 days. The percentage of SubG1 cells was evaluated using propidium iodide staining and flow cytometry. Mean values ± s.d. of four independent experiments are presented (lower panel). P -values < 0.05 are indicated by asterisks.

Article Snippet: MCF7 and T47D cells were purchased from ATCC, BT474 cells were purchased from CLS Cell Line Services GmbH (Heidelberg, Germany) and MDA-MB-361 cells were purchased from Sigma Aldrich (Taufkirchen, Germany).

Techniques: Cell Culture, Western Blot, Expressing, Control, Staining, Flow Cytometry

Journal: Oncotarget

Article Title: Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells

doi: 10.18632/oncotarget.20261

Figure Lengend Snippet: ( A ) BT474 cells were cultured in the absence or in the presence of the indicated concentrations and combinations of lapatinib, fulvestrant, carfilzomib and bortezomib. Where fulvestrant was used, it was administrated 4 hours before treatment with other drugs. After 30 hours cells were harvested. Western blots of the protein lysates were probed with the indicated antibodies. ( B ) To determine the induction of cell death in response to the indicated drug combinations equal numbers of BT474 cells were seeded on 12-well culture plates and cultured in the absence or in the presence of the indicated drug concentrations. The percentage of SubG1 cells was evaluated at different time points using propidium iodide staining and flow cytometry. Mean values ± s.d. of three independent experiments are presented. ( C ) Equal numbers of BT474 cells were seeded on 6-well culture plates and cultured either with or without the indicated drug combinations. After 8 days cells were fixed. Macroscopic photos are shown of the fixed cell colonies for BT474 cells either (a) untreated or treated with (b) lapatinib [125 nM] plus fulvestrant [1 μM], (c) bortezomib [30 nM], (d) bortezomib [30 nM] plus lapatinib [125 nM] plus fulvestrant [1 μM] or (e) carfilzomib [125 nM] and (f) carfilzomib [125 nM] plus lapatinib [125 nM] plus fulvestrant [1 μM]. Bar 100 μm.

Article Snippet: MCF7 and T47D cells were purchased from ATCC, BT474 cells were purchased from CLS Cell Line Services GmbH (Heidelberg, Germany) and MDA-MB-361 cells were purchased from Sigma Aldrich (Taufkirchen, Germany).

Techniques: Cell Culture, Western Blot, Staining, Flow Cytometry